To aid COVID-19 research efforts, NVIDIA has developed new artificial intelligence models, genomic sequencing software, and speech recognition technologies for the medical community. The new capabilities are a major expansion of the NVIDIA Clara healthcare platform, and will help healthcare researchers, technology solutions providers, and hospitals combat the pandemic faster. NVIDIA released a set of AI models that can help researchers detect and study infected patients through chest CT scan data. NVIDIA is also leading a multinational COVID-19 federated learning initiative in partnership with Mass General Brigham. The initiative aims to expand COVID-19 AI models to x-ray imaging that enables local adaptation without sharing patient data and protecting patient privacy. In addition to the AI models, NVIDIA is also making computational genomics software freely available to COVID-19 researchers. The software, called NVIDIA Clara Parabricks, achieved a new speed record by analyzing the whole human genome DNA sequence in under 20 minutes. NVIDIA has also introduced GPU-accelerated RNA-sequencing pipelines that return results in less than two hours, providing researchers with critical insights about patients’ susceptibility to disease, disease progression, and response to treatment. NVIDIA has also launched NVIDIA Clara Guardian, a platform that uses intelligent video analytics and automatic speech recognition technologies to help a new generation of smart hospitals perform vital sign monitoring while limiting staff exposure. With these new capabilities, researchers, developers, and hospitals across the healthcare continuum can further combat, track, and treat COVID-19.
Zebra Medical Vision, the deep-learning medical imaging analytics company, announced its fifth FDA 510(k) clearance for its Vertebral Compression Fractures (VCF) product. The solution automatically identifies findings suggestive of compression fractures, enabling clinicians to place patients that are at risk of osteoporosis in treatment pathways to prevent potentially life-changing fractures. The VCF product expands the company’s growing AI1™ (all-in-one) bundle of FDA cleared AI solutions, which has now received a fourth US patent in its bone health series. Nearly half of all women and a quarter of men over the age of 50 will suffer an osteoporotic fracture in their lifetime. According to the National Osteoporosis Foundation (NOF), the cost of osteoporosis-related fragility fractures to the U.S. is estimated to be $52 billion annually. Osteoporosis, also referred to as “The Silent Killer,” is the most common preventable cause of fractures, causing more than 2 million cases of broken bones in the U.S. alone every year. “Zebra-Med's latest AI solution will be advantageous to value-based healthcare systems. With appropriate intervention, it has potential to reduce secondary fractures in high risk patients and reduce additional related costs, while enabling providers to benefit from higher Medicare star ratings and increased revenue from RAF score adjustments, ” says Dr. Keith White, Medical Director of Imaging Services, Intermountain Health.
Looking for news updates personalized to your needs? Claim your BioTrack invite and get the latest market and research activity customized by news type, source, keywords and more.
Headlines curated by BioTrack beta and edited by Seth Schachter, Associate at DeciBio Consulting
If you would like to discuss the field of big data and AI in healthcare in more detail or provide feedback on our newsletters, please don't hesitate to reach out to me at Schachter@decibio.com or connect with me on LinkedIn
